PRQR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders...

Stats
Today's Volume	182 493
Average Volume	228 279
Market Cap	150.32M
EPS	€0 ( 2024-04-03 )
Next earnings date	( €-0.120 ) 2024-05-21
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.17
ATR14	€0.0170 (0.90%)

Volume Correlation

Long: -0.31 (neutral)

Short: -0.56 (weak negative)

Signal:(50.346) Neutral

ProQR Therapeutics NV Correlation

10 Most Positive Correlations
ECHO	0.961
SIOX	0.958
MLVF	0.954
IIN	0.95
CDZI	0.949
EXAS	0.942
BTWN	0.94
EXFO	0.934
GDNR	0.933
BKCH	0.932

10 Most Negative Correlations
SNPX	-0.971
UTME	-0.963
ISPO	-0.956
PDBC	-0.95
LARK	-0.944
KTTA	-0.943
RIVN	-0.937
OP	-0.936
HMNF	-0.934
PIII	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ProQR Therapeutics NV Correlation - Currency/Commodity

0.73
( moderate )

0.90
( strong )

0.00
( neutral )

0.73
( moderate )

0.00
( neutral )

0.60
( weak )

ProQR Therapeutics NV Financials

Annual	2023
Revenue:	€6.38M
Gross Profit:	€6.38M (100.00 %)
EPS:	€-0.340

Q4	2023
Revenue:	€3.20M
Gross Profit:	€3.20M (100.00 %)
EPS:	€-0.0681

Q3	2023
Revenue:	€1.37M
Gross Profit:	€1.37M (100.00 %)
EPS:	€-0.0705

Q2	2023
Revenue:	€1.21M
Gross Profit:	€1.21M (100.00 %)
EPS:	€-0.0988

Financial Reports:

No articles found.

ProQR Therapeutics NV

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.